

LIVE INTERACTIVE CE WEBINAR
COPE CREDIT APPROVED

Overcoming the Glaucoma Treatment Burden with Standalone and Combined MIGS

SUNDAY, JANUARY 24, 2021
8AM – 11AM PT (11AM – 2PM ET)



Provided by Evolve Medical Education



Kristopher A. May, OD, FAAO



Leslie O'Dell, OD, FAAO



Deborah Ristvedt, DO



Justin Schweitzer, OD, FAAO

Supported by an unrestricted educational grant from Sight Sciences

Credit Designation Statement:

Evolve Medical Education, LLC is an approved COPE administrator.

This course is COPE approved for 3 hours.

COPE Course ID #70685-GL

Activity ID #120868

Grantor Statement:

Supported by an unrestricted educational grant from Sight Sciences.

Learning Objectives

1. Review the impact of patient compliance on conventional glaucoma treatment outcomes
2. Identify the importance of earlier intervention with the glaucoma patient, regardless of disease severity levels
3. Compare and contrast standalone and cataract MIGS (minimally invasive glaucoma surgery) patients: Patient demographics, surgical procedure, and patient follow-up parameters
4. Describe the impact of resistance in different outflow pathways on glaucoma patient outcomes
5. Identify the efficacy levels, short-term complication rates and long-term tissue removal risks of various glaucoma surgical procedures
6. Understand the MIGS patient journey: How to identify ideal MIGS patients, educate and set expectations, and manage these patients postop

Disclosure Policy

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

Editorial Support Disclosures

- Erin K. Fletcher, MIT, director of compliance and education, Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.

Faculty Disclosures

- **Kristopher A. May, OD, FAAO**, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of *Consultant*: Alcon, Sight Sciences; *Speaker's Bureau*: Alcon, Bausch + Lomb, Sight Sciences
- **Leslie O'Dell, OD, FAAO**, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of *Consultant*: Aerie, Sight Sciences
- **Deborah Ristvedt, DO**, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of *Consultant*: Allergan, Glaukos, and Sight Sciences. *Grant/Research Support*: Allergan; *Speaker's Bureau*: Alcon, and Glaukos
- **Justin Schweitzer, OD, FAAO**, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of *Consultant*: Allergan, Ocular Therapeutix, EyePoint, Dompe, Reichert, Horizon, Alcon, Bausch + Lomb; *Grant/Research Support*: Glaukos; *Speaker's Bureau*: Aerie, Alcon, Allergan, Bausch + Lomb, Sight Sciences, Sun, Quidel, Glaukos; *Stock/Shareholder*: Equinox

Submit Your Questions

- This is a **live interactive** program, so submit your questions using the Q&A box at any time

Claim Credit

- To claim credit for this meeting, you must register or log onto the Evolve Medical Education website: <https://evolvemeded.com> and complete the Activity Evaluation Form at: <https://evolvemeded.com/online-courses/2041-migs-live/>
- COPE Credits will be reported to ARBO.
- You will receive an email with this link on January 25, 2021.

Today's Program: Overcoming the Glaucoma Treatment Burden with Standalone and Combined MIGS

Faculty



Kristopher A. May, OD, FAAO



Leslie O'Dell, OD, FAAO



Deborah Ristvedt, DO



Justin Schweitzer, OD, FAAO

Agenda

- **The Burden of Glaucoma: How Noncompliance Impacts Patients and Doctors** – Leslie O'Dell
- **MIGS: What Is It and What Outflow Pathways Does It Target** – Deborah Ristvedt
- **Early Intervention with MIGS: Standalone and Combined with Cataract Surgery** – Justin Schweitzer
- **Case Studies: Common MIGS Scenarios** – All Faculty

Audience Question #1

Where do you practice?

- a) Northeast
- b) South
- c) Midwest
- d) West
- e) Canada/Other

Audience Question #2

How many years have you been practicing, outside of school/training?

- a) 0 (current student/in-training)
- b) 1-5
- c) 5-10
- d) 10-15
- e) >15

Audience Question #3

How many cataract surgery procedures do you refer out or co-manage each week?

- a) None
- b) 1 to 5
- c) 6 to 10
- d) 11 to 15
- e) 16 to 20
- f) More than 20

Audience Question #4

Approximately how many glaucoma patients do you see each month?

- a) None
- b) 1-20
- c) 11-20
- d) 21-40
- e) More than 40

Audience Question #5

How many MIGS (minimally invasive glaucoma surgery) patients do you co-manage or refer each year?


- a) None
- b) 1-5
- c) 6-10
- d) 11-20
- e) More than 20

Audience Question #6

How confident are you in your understanding of the short and long-term benefits of MIGS procedures?


- a) Very confident
- b) Confident
- c) Neutral
- d) Not so confident
- e) Not confident at all

What percent of your patients currently prescribed _____ topical medication(s) to control their glaucoma, do you believe are not compliant?



On average, **32%** of patients on 1 topical medication and **25%** of patients on more than 2 topical medications are believed to be noncompliant

What percentage of your glaucoma patients would you estimate are candidates for a minimally invasive glaucoma surgery (MIGS) procedure?



Audience Question #7

What percent of your patients currently prescribed TWO OR MORE topical medication(s) to control their glaucoma, do you believe are NOT COMPLIANT?

- a) 0% are not compliant
- b) 1-20% are not compliant
- c) 21-40% are not compliant
- d) 41-60% are not compliant
- e) 61-80% are not compliant
- f) 81-100% are not compliant

The Burden of Glaucoma: How Noncompliance Impacts Patients and Doctors

Leslie O'Dell, OD, FAAO

Prevalence of Glaucoma

- **80 million worldwide**¹
 - Expected to increase to over 111 million by 2040²
- **3.3 million in US**³
 - Estimated to affect 6 million by 2050⁴
- **Glaucoma costs the US economy \$2.86 billion every year** in direct costs and productivity losses¹



1. Rein DB, et al. Archives of ophthalmology. 2006 Dec 1;124(12):1754-60.
2. Tham YC, et al. Ophthalmology. 2014 Nov 1;121(11):2081-90.
3. Ferris FL, Tielsch JM. Archives of Ophthalmology. 2004 Apr 1;122(4):451-2.
4. <https://www.brightfocus.org/>

Following Doctor's Orders: Adherence vs. Compliance


ADHERENCE

- Proactive choice for patients to follow through
- Patients take responsibility for their own well being
- For example: refill their prescriptions and take the medicines

COMPLIANCE

- Passive behavior
- Patients follow a list of doctor's instructions
- "Do what he or she is told"


What percent of your patients currently prescribed _____
topical medication(s) to control their glaucoma, do you believe
are not compliant?



On average, 32% of patients on 1 topical medication and
25% of patients on more than 2 topical medications
are believed to be noncompliant

Compliance in Glaucoma

- In one glaucoma study, only **58%** of patients were adherent to a TID eyedrop regimen *despite being informed that nonadherence would cause them to go blind*¹



1. Clay Mann N, World Health Organization. 1993.

- One study of glaucoma monotherapy found that **25%** of patients took **less than 75%** of their doses²
- Almost **20%** of patients took **less than 50%** of their doses *even when they knew they were being electronically monitored*²



2. Okeke CO, et al. Ophthalmology. 2009;116:191-199.

Difficulties with Drops

- They may burn on application



Difficulties with Drops

- They may burn on application
- Patients forget to take every dose



Difficulties with Drops

- They may burn on application
- Patients forget to take every dose
- Patients may have difficulty applying drops accurately, especially for older patients
 - Physical limitations:
 - Stroke
 - Alzheimer's disease
 - Paraplegia/quadriplegia
 - Parkinson's disease
 - Arthritis



Difficulties with Drops

- They may burn on application
- Patients forget to take every dose
- Patients may have difficulty applying drops accurately, especially for older patients
- Hit or miss of renewal of costly prescriptions that run out at different times



Difficulties with Drops

- They may burn on application
- Patients forget to take every dose
- Patients may have difficulty applying drops accurately, especially for older patients
- Hit or miss of renewal of costly prescriptions that run out at different times
- Social stigma of the possibility of developing red eyes



Difficulties with Drops

- They may burn on application
- Patients forget to take every dose
- Patients may have difficulty applying drops accurately, especially for older patients
- Hit or miss of renewal of costly prescriptions that run out at different times
- Social stigma of the possibility of developing red eyes
- Add to the burden of using medicines day in and day out for a disease that they don't believe they have, cannot feel, or self-monitor



The Problem with Multiple Drops

- Increased exposure to preservatives
- Reduced efficacy with the addition of more drops



Increasing the number of bottles...



Increases risk of
non adherence by

60%

Increasing daily doses...



Increases risk of
non adherence by

32%

Multiple
Drops
Can Lower
Adherence

Drops Impact Quality of Life

- Cost
- Outcomes management
- Side effects
- Fluctuations of IOP
- Compliance
- Impact on other family members



Panel Discussion

1. What is the impact of patient noncompliance on conventional glaucoma treatment outcomes?
2. Who is most likely to be noncompliant with topical drops?
3. How do you make treatment decisions for patients based on noncompliance ?
4. How important should treatment solutions/technologies that address compliance be to optometrists?